Premium
Analysis of aberrant somatic hypermutation (SHM) in non‐Hodgkin's lymphomas of patients with chronic HCV infection
Author(s) -
Libra Massimo,
Capello Daniela,
Gloghini Annunziata,
Laura Pasqualucci,
Berra Eva,
Cerri Michaela,
Gasparotto Daniela,
Franca Stivala,
De Re Valli,
Gaidano Gianluca,
Carbone Antonino
Publication year - 2005
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1754
Subject(s) - somatic hypermutation , virology , somatic cell , medicine , immunology , biology , genetics , antibody , b cell , gene
Hepatitis C virus (HCV) and aberrant somatic hypermutation (SHM) have each been suggested to contribute to the development of B‐cell non‐Hodgkin's lymphoma (NHL). The incidence of PIM‐1, PAX‐5, RhoH / TTF , and c‐ MYC mutations in tumour biopsy specimens from 32 HCV‐infected B‐cell NHL patients was analysed to determine whether the extent of aberrant SHM among these patients differed from that previously reported for HCV‐negative B‐cell NHL patients. Mutation of PIM‐1, PAX‐5, RhoH / TTF , and c‐ MYC was detected in 4 (13%), 5 (16%), 4 (13%), and 4 (13%) of 32 samples, respectively. In HCV‐positive B‐cell NHL patients, the frequency of aberrant SHM was lower than that already found in HCV‐negative B‐cell NHL patients. This indicates that, unlike B‐cell lymphomas from HCV‐negative patients, aberrant SHM may not contribute significantly to malignant transformation in HCV‐associated B‐cell lymphomas. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.